Magenta Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Magenta Therapeutics, Inc. (MGTA) operates as a clinical-stage biotechnology company following its 2023 merger with Dianthus Therapeutics, Inc., through which it now focuses on developing next-generation complement inhibitors for autoimmune diseases; its lead product candidate, DNTH103 (claseprubart), is a selective active C1s monoclonal antibody in Phase 3 trials for chronic inflammatory demyelinating polyneuropathy and Phase 2 trials for generalized myasthenia gravis and multifocal motor neuropathy, with subcutaneous self-administration every two weeks, extended half-life, and high potency. The company previously developed stem cell transplant therapies including targeted conditioning agents MGTA-117 and CD45-antibody drug conjugate, and stem cell mobilizers MGTA-145 and MGTA-456, aimed at blood cancers, genetic diseases, and autoimmune disorders, but shifted strategic focus post-merger to Dianthus' pipeline. Founded in 2016 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics conducts operations primarily in the United States with global clinical trial reach; it completed a reverse merger with Dianthus in September 2023, implemented a reverse stock split, and rebranded the combined entity under Dianthus Therapeutics, Inc. on Nasdaq, securing $70 million in private investment from investors including Fidelity Management & Research Company and 5AM Ventures to advance DNTH103, which recently completed enrollment in its Phase 2 MaGic trial exceeding targets with top-line data expected in September 2025.
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
10 Best-Performing Penny Stocks in the Health Care Sector
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
MGTA Stock: 51.66% Surge Explained
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
Magenta Therapeutics Trims R&D, Cuts Workforce
Big Pharma Is Going Holiday Shopping. Who's Next?
Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting
Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference